Literature DB >> 23518442

Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge.

D T Geraets1, R van Baars, I Alonso, J Ordi, A Torné, W J G Melchers, C J L M Meijer, W G V Quint.   

Abstract

BACKGROUND: High-risk human papillomavirus (hrHPV) testing in cervical screening is usually performed on physician-taken cervical smears in liquid-based medium. However, solid-state specimen carriers allow easy, non-hazardous storage and transportation and might be suitable for self-collection by non-responders in screening and in low-resource settings.
OBJECTIVES: We evaluated the adequacy of self-collected cervicovaginal (c/v) samples using a Viba-brush stored on an Indicating FTA-elute cartridge (FTA-based self-sampling) for hrHPV testing in women referred to a gynecology clinic due to an abnormal smear. STUDY
DESIGN: 182 women accepted to self-collect a c/v sample. After self-sampling, a physician obtained a conventional liquid-based cervical smear. Finally, women were examined by colposcopy and a biopsy was taken when clinically indicated. Self-samples required only simple DNA elution, and DNA was extracted from physician-obtained samples. Both samples were tested for 14 hrHPVs by GP5+/6+-EIA-LQ Test and SPF(10)-DEIA-LiPA(25).
RESULTS: Both assays detected significantly more hrHPV in physician-collected specimens than in self-collected samples (75.3% and 67.6% by SPF(10); 63.3% and 53.3% by GP5+/6+, respectively). The combination of physician-collected specimen and GP5+/6+ testing demonstrated the optimal balance in sensitivity (98.0%) and specificity (48.1%) for CIN2+ detection in this referral population. A test system of FTA-based self-collection and SPF(10) hrHPV detection approached this sensitivity (95.9%) and specificity (42.9%).
CONCLUSIONS: These results show that the clinical performance of hrHPV detection is determined by both the sample collection system and the test method. FTA-based self-collection with SPF(10) testing might be valuable when a liquid-based medium cannot be used, but requires further investigation in screening populations.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23518442     DOI: 10.1016/j.jcv.2013.02.016

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  12 in total

Review 1.  Molecular oncology testing in resource-limited settings.

Authors:  Margaret L Gulley; Douglas R Morgan
Journal:  J Mol Diagn       Date:  2014-09-19       Impact factor: 5.568

2.  An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain.

Authors:  Khairya Moosa; Adel Salman Alsayyad; Wim Quint; Kusuma Gopala; Rodrigo DeAntonio
Journal:  BMC Cancer       Date:  2014-12-03       Impact factor: 4.430

3.  Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.

Authors:  Inger Gustavsson; Riina Aarnio; Malin Berggrund; Julia Hedlund-Lindberg; Ann-Sofi Strand; Karin Sanner; Ingrid Wikström; Stefan Enroth; Matts Olovsson; Ulf Gyllensten
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

4.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.

Authors:  Marc Arbyn; Sara B Smith; Sarah Temin; Farhana Sultana; Philip Castle
Journal:  BMJ       Date:  2018-12-05

Review 5.  Screening of Cervical Cancer with Self-Collected Cervical Samples and Next-Generation Sequencing.

Authors:  Yubo Fan; Yifan Meng; Shuo Yang; Ling Wang; Wenhua Zhi; Cordelle Lazare; Canhui Cao; Peng Wu
Journal:  Dis Markers       Date:  2018-11-14       Impact factor: 3.434

6.  Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Authors:  D T Geraets; K Cuschieri; M N C de Koning; L J van Doorn; P J F Snijders; C J L M Meijer; W G V Quint; M Arbyn
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

7.  Human papillomavirus prevalence and type distribution among women attending routine gynecological examinations in Saudi Arabia.

Authors:  Abdulaziz AlObaid; Ismail A Al-Badawi; Hanan Al-Kadri; Kusuma Gopala; Walid Kandeil; Wim Quint; Murad Al-Aker; Rodrigo DeAntonio
Journal:  BMC Infect Dis       Date:  2014-12-14       Impact factor: 3.090

8.  Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening.

Authors:  Shao-Ming Wang; Shang-Ying Hu; Wen Chen; Feng Chen; Fang-Hui Zhao; Wei He; Xin-Ming Ma; Yu-Qing Zhang; Jian Wang; Priya Sivasubramaniam; You-Lin Qiao
Journal:  BMC Cancer       Date:  2015-11-04       Impact factor: 4.430

9.  Randomized Comparison of Two Vaginal Self-Sampling Methods for Human Papillomavirus Detection: Dry Swab versus FTA Cartridge.

Authors:  Rosa Catarino; Pierre Vassilakos; Aline Bilancioni; Mathieu Vanden Eynde; Ulrike Meyer-Hamme; Pierre-Alain Menoud; Frédéric Guerry; Patrick Petignat
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

10.  An Evaluation of the Cobas4800 HPV Test on Cervico-Vaginal Specimens in Liquid versus Solid Transport Media.

Authors:  Hongxue Luo; Hui Du; Kathryn Maurer; Jerome L Belinson; Guixiang Wang; Zhihong Liu; Lijie Zhang; Yanqiu Zhou; Chun Wang; Jinlong Tang; Xinfeng Qu; Ruifang Wu
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.